Confined or spread disease-Spread with distant metastasis Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread with distant metastasis Posts on Medivizor

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Posted by on Jan 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR (epidermal growth factor receptor) plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with 5-fluorouracil...

Read More

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Posted by on Dec 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients. Some background Colorectal...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Posted by on Dec 19, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...

Read More

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Posted by on Oct 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these...

Read More

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus fluorouracil and folinic acid in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus fluorouracil and folinic acid in patients with RAS wild-type metastatic colorectal cancer.

Posted by on Oct 16, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of panitumumab (Vectibix) when added to maintenance therapy with fluorouracil (Adrucil) and folinic acid (Leucovirin) (FU/FA) in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with FU/FA plus panitumumab was safe and...

Read More

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Posted by on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...

Read More

Evaluating the effectiveness and safety of different bevacizumab schedules in combination with chemotherapy for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness and safety of different bevacizumab schedules in combination with chemotherapy for the treatment of patients with metastatic colorectal cancer.

Posted by on Aug 29, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) administered either on the same day or a few days before chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab administered 4 days before chemotherapy significantly improved overall survival with...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

Posted by on Aug 8, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Is pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?

Is pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?

Posted by on Jul 11, 2021 in Melanoma | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...

Read More

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between pyrotinib (SHR-1258) and trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2+ metastatic breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data showed that pyrotinib may be more effective than T-DM1 for these patients. Some...

Read More